1. Home
  2. ATR vs PRAX Comparison

ATR vs PRAX Comparison

Compare ATR & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AptarGroup Inc.

ATR

AptarGroup Inc.

N/A

Current Price

$129.08

Market Cap

7.7B

Sector

Industrials

ML Signal

N/A

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

N/A

Current Price

$323.04

Market Cap

7.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ATR
PRAX
Founded
1992
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Plastic Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
7.1B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
ATR
PRAX
Price
$129.08
$323.04
Analyst Decision
Buy
Strong Buy
Analyst Count
4
15
Target Price
$170.25
$572.13
AVG Volume (30 Days)
393.1K
514.9K
Earning Date
04-30-2026
05-08-2026
Dividend Yield
1.56%
N/A
EPS Growth
6.51
N/A
EPS
1.12
N/A
Revenue
$3,777,181,000.00
N/A
Revenue This Year
$5.18
N/A
Revenue Next Year
$4.98
$7,758.26
P/E Ratio
$115.43
N/A
Revenue Growth
5.42
N/A
52 Week Low
$103.23
$37.25
52 Week High
$164.28
$366.52

Technical Indicators

Market Signals
Indicator
ATR
PRAX
Relative Strength Index (RSI) 68.00 50.02
Support Level $121.60 $307.93
Resistance Level $132.42 $327.65
Average True Range (ATR) 2.31 19.92
MACD 0.31 -0.36
Stochastic Oscillator 90.36 15.05

Price Performance

Historical Comparison
ATR
PRAX

About ATR AptarGroup Inc.

Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: